Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data.Romiplostim dose response in patients with immune thrombocytopenia.Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.Clinical population pharmacokinetics and toxicodynamics of linezolid.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suPlatelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinPerformance in population models for count data, part II: a new SAEM algorithmPopulation pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria.Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Evaluation of different tests based on observations for external model evaluation of population analyses.PKreport: report generation for checking population pharmacokinetic model assumptions.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensPharmacokinetic alteration of baclofen by multiple oral administration of herbal medicines in ratsPopulation pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.Population pharmacokinetic meta-analysis of vortioxetine in healthy individualsPilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical modelComparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulationPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Comparative performance of cell life span and cell transit models for describing erythropoietic drug effectsIntraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyPredictive Performance of a Vancomycin Population Pharmacokinetic Model in NeonatesA bodyweight-dependent allometric exponent for scaling clearance across the human life-span.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical PracticeModel Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.
P2860
Q27687599-7A0CB44D-CC50-4BED-BF18-9078E966EB27Q30844731-587B0979-A498-4C80-AB49-65CED9C3DBA7Q31127244-164952CB-93EE-4A5B-99C2-ED67E310C5B0Q33398730-66142296-1C41-43A3-9A56-E608E0D5D73FQ33408198-5245129A-1470-43A2-A4EC-3396EC21A43AQ33413269-460DA42A-692C-49C1-9E53-6B782FE66754Q33415594-D637B2D6-7904-4BBF-AEDA-CED568BE9387Q33416659-A21E174E-62B9-443F-A52D-7E378D744A33Q33427607-35848D8D-123C-4726-B5CC-B9A312E39149Q33493457-3018D99E-0906-4A53-A1A4-3DD569461C11Q33708140-4E719AF1-784A-465B-9C74-0F6B1AEFDF4AQ33713272-EFC52F6C-6E57-4E8A-A3AF-21B15FFD0952Q33797950-000AC748-B7A7-445F-BC9F-F2E421483051Q33869167-4D607482-B9A8-4FA3-BD60-100934BAF665Q33901595-FE90490E-797B-467A-90D1-AD5F3C79C084Q34065294-FF05CCDC-17BC-44C6-B668-6EC8110FA81BQ34189102-24556041-C50C-43DC-A53F-FF8C8EDC4E47Q34227492-24013ECF-C0D6-49CF-A220-D0A4A7710E0BQ34381321-7BAD4823-2E53-4E60-90A4-AE7E3ADB29FDQ34501161-0824EC90-B75E-454F-99BB-7237D0DB9169Q34596303-68C51330-D064-4A62-BF6C-408BAD48D86FQ34639656-858B0A49-A49E-4E35-9CED-FFB79E9BBF48Q34700914-D5856068-1094-488F-8314-0C4605BA9E23Q34737693-52CAE6D5-B5E4-49D1-A0D8-D8AAB80C35FBQ35005118-0F114FD8-C03D-42CA-BA15-7A8717416364Q35053910-CAE36778-2915-403E-97B9-FF1D4B998C72Q35168882-FA98B746-0B64-4746-B988-3930DBFE5524Q35210471-301EFBA2-92A6-4A5C-9FD8-821348017C54Q35364120-91505A46-3B0C-4544-9036-7EB5695244D0Q35595803-ABDBBFF5-84CD-42F9-BC8F-EAEFBCDBC36BQ35739551-AB289427-FE9C-47AF-9806-69E5FA1DCD50Q35752756-231E91F6-3BA2-4ED8-8112-D66654E06042Q35949142-96F8765B-40A4-424A-A691-F8BE57DD9E4CQ35960706-F83B1091-4239-4DC8-B553-EBE46C016DE9Q35967888-BD4FC2C1-AC83-4489-854D-39C55F27DD1EQ35968259-36FCB0D3-83B3-4A48-994B-4CAD46932883Q36036400-37682462-9CE4-481E-9821-6163C1E0AA42Q36075844-21A9783A-CEC8-4757-970C-4E790A1B8E1BQ36203402-C01F5E67-6135-4C93-B936-56B31753AFC9Q36234379-9E84A155-97E8-481B-ADF7-6E26C1B2173F
P2860
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Metrics for external model eva ...... harmacokinetics of gliclazide.
@en
Metrics for external model eva ...... harmacokinetics of gliclazide.
@nl
type
label
Metrics for external model eva ...... harmacokinetics of gliclazide.
@en
Metrics for external model eva ...... harmacokinetics of gliclazide.
@nl
prefLabel
Metrics for external model eva ...... harmacokinetics of gliclazide.
@en
Metrics for external model eva ...... harmacokinetics of gliclazide.
@nl
P2093
P2860
P1476
Metrics for external model eva ...... harmacokinetics of gliclazide.
@en
P2093
Christian Laveille
Céline Laffont
Emmanuelle Comets
France Mentré
Karl Brendel
P2860
P304
P356
10.1007/S11095-006-9067-5
P577
2006-08-12T00:00:00Z